CS
MRSN

Candriam SCA’s Mersana Therapeutics MRSN Stock Holding History

Candriam SCA’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-96,619
Closed -$7.95M – 680
2023
Q2 		$7.95M Sell
96,619
-21,895
-18% -$3.2M 0.06% 274
2023
Q1 		$11.2M Buy
118,514
+10,800
+10% +$1.52M 0.08% 243
2022
Q4 		$15.8M Buy
107,714
+7,800
+8% +$1.32M 0.11% 197
2022
Q3 		$16.9M Buy
99,914
+20,292
+25% +$3.3M 0.12% 187
2022
Q2 		$9.2M Buy
79,622
+5,829
+8% +$548K 0.08% 237
2022
Q1 		$7.36M Sell
73,793
-7,123
-9% -$832K 0.05% 295
2021
Q4 		$12.6M Hold
80,916
– – 0.08% 231
2021
Q3 		$19.1M Buy
80,916
+2,000
+3% +$584K 0.13% 183
2021
Q2 		$26.8M Buy
78,916
+34,029
+76% +$12.9M 0.18% 131
2021
Q1 		$28.7M Buy
44,887
+1
+0% +$485 0.24% 110
2020
Q4 		$29.9M Buy
44,886
+21,378
+91% +$11.9M 0.24% 110
2020
Q3 		$10.9M Sell
23,508
-322
-1% -$163K 0.1% 217
2020
Q2 		$13.9M Buy
+23,830
New +$8.14M 0.15% 166
2018
Q2 		– Sell
-1,440
Closed -$568K – 814
2018
Q1 		$568K Buy
1,440
+960
+200% +$379K 0.01% 662
2017
Q4 		$197K Buy
+480
New +$209K ﹤0.01% 742

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Candriam SCA's MRSN Position: Q3 2023 in Review

Candriam SCA sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 96,619 shares — an estimated $7.95M sold.

Candriam SCA first reported a position in MRSN in Q4 2017 and held it in 15 quarters. The position peaked at $29.9M in Q4 2020. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Candriam SCA reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Candriam SCA sold 96,619 Mersana Therapeutics shares in Q3 2023, an estimated $7.95M.
  • Candriam SCA first reported a position in Mersana Therapeutics in Q4 2017 and held it in 15 quarters.
  • Candriam SCA's Mersana Therapeutics position peaked at $29.9M in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.